Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

IO102/IO103 and Nivolumab-Relatlimab Fixed Dose Combination for the Treatment of Patients with Untreated, Unresectable Stage III/IV Melanoma

Trial Status: active

This phase II trial tests the safety and effectiveness of IO102/IO103 given with nivolumab/relatlimab-rmbw (nivolumab-relatlimab fixed dose combination [FDC]) in treating patients with untreated stage III/IV melanoma that cannot be removed with surgery (unresectable). IO102/IO103 is a vaccine made up of two parts. IO102 is designed to destroy cells that make (express) a protein called indoleamine 2,3-dehydrogenase (IDO) and IO103 is designed to destroy cells that express a protein called programmed cell death ligand 1 (PD-L1). IDO and PD-L1 are immunosuppressive proteins, meaning they prevent the immune system from attacking the tumor cells. By destroying cells that express these immunosuppressive proteins, IO102/IO103 may help the immune system better recognize and kill tumor cells. Nivolumab-relatlimab FDC is a combination drug formulation of two monoclonal antibodies, nivolumab and relatlimab, in fixed doses. Nivolumab and relatlimab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Giving IO102/IO103 in combination with nivolumab-relatlimab FDC may kill more tumor cells in patients with untreated, unresectable stage III/IV melanoma.